Finnhub•2026-04-16
Vir Biotechnology, Inc. Receives $240 Million Upfront Payment and $75 Million Equity Investment from AstellasVIR — Vir Biotechnology Inc
NASDAQ · Biotechnology · Biotechnology
$10.83+65.34%Market cap1.48B
- Latest Close
- $10.83
- 30-Day Move
- +65.3%
- Market Cap
- $1.5B
- Shares Outstanding
- 159,770,000
- P/B Ratio
- 1.1
- ROE
- -57.2%
Analyst consensus: Buy · 14 analysts
NASDAQ:VIRBiotechnology / BiotechnologyDelayed public snapshot
Vir Biotechnology Inc
A read-only Alphactor snapshot forVir Biotechnology Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$10.83
30-Day Move
+65.3%
Market Cap
$1.5B
Shares Outstanding
159,770,000
P/B Ratio
1.1
ROE
-57.2%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$10.83
+65.3%last 90 delayed daily bars
Market cap$1.5B
90D High
$11.66
90D Low
$5.55
Avg Volume
3,012,076
What stands out
Gross margin is running at 100.0%, which gives a quick read on operating quality before you open the full model.
Net margin is -638.9%, useful for comparing VIR against peers in Biotechnology.
VIR is up 65.3% over the last 30 trading days shown on this page.
Latest operating income is $-480M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$2.92
Rule of 40
-591.8%
Dark Pool Short %
46.3%
Fundamentals snapshot
Latest Close
$10.83
30-Day Move
+65.3%
Market Cap
$1.5B
Shares Outstanding
159,770,000
P/B Ratio
1.1
ROE
-57.2%
ROA
-43.7%
Gross Margin
100.0%
Operating Margin
-699.2%
Net Margin
-638.9%
Debt / Equity
0
Current Ratio
5.54
Latest Revenue
$67M
Financial statement snapshot
Revenue
$67M
Gross Profit
$66M
Operating Income
$-480M
Net Income
$-438M
Gross Margin
9996.0%
Net Margin
-63887.0%
Current Ratio
5.54
Debt / Equity
0.00
Valuation snapshot
Fair Value
$2.92
Upside / Downside
-73.0%
Signal
Overvalued
Implied Growth
--
EV/Rev
$2.92
Growth Assumption
-10.0%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
Current Price
$10.83
Composite Fair Value
$2.92
EV/Rev
$2.92
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Quality snapshot
Altman Z
1.06
Distress
Piotroski
4
Moderate (4-6)
Cash Conversion
0.89x
Rule of 40
-591.8%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.6B | $833M | $516M | $1.6B |
| 2023-12-31 | $39M | $-671M | $-615M | $-800M |
| 2024-12-31 | $64M | $-552M | $-522M | $-454M |
| 2025-12-31 | $67M | $-480M | $-438M | $-397M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-16
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate CancerAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$21M
Buys
0
Sells
55
Buy Value
$0
Sell Value
$21M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-06 | De Backer Marianne | Sell | 72,559 | $9.16 |
| 2026-04-01 | SATO VICKI L | Sell | 22,000 | $9.07 |
| 2026-03-23 | Sabatini Brent | Sell | 7,711 | $9.12 |
| 2026-03-20 | O'Byrne Jason | J | 2,500 | $0.00 |
| 2026-03-20 | O'Byrne Jason | J | 2,500 | $0.00 |
| 2026-03-02 | SATO VICKI L | Sell | 200 | $9.98 |
| 2026-03-02 | SATO VICKI L | Sell | 21,800 | $9.50 |
| 2026-02-25 | Eisner Mark | Sell | 1,889 | $9.82 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5,778,202 | 0.04% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3,497,089 | 0.02% | 2025-12-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,645,083 | 0.02% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2,529,316 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 2,154,318 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1,422,744 | 0.01% | 2025-12-31 |
| SPDR SERIES TRUST-State Street SPDR Portfolio S&P 600 Small Cap ETF | 1,037,187 | 0.01% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1,011,770 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$168M
--
Vanguard Group
Filed 2025-05-09
$83M
-2.5%
FMR LLC (Fidelity)
Filed 2026-02-17
$19M
-13.2%
Citadel Advisors
Filed 2025-08-14
$17M
--
Geode Capital Management
Filed 2026-02-09
$14M
+3.6%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.21
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
14
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.